BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 15268672)

  • 1. Enhancement of vaccine potency through improved delivery.
    Ulmer JB
    Expert Opin Biol Ther; 2004 Jul; 4(7):1045-51. PubMed ID: 15268672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens.
    Perrie Y; Mohammed AR; Kirby DJ; McNeil SE; Bramwell VW
    Int J Pharm; 2008 Dec; 364(2):272-80. PubMed ID: 18555624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subunit-based mucosal vaccine delivery systems for pulmonary delivery - Are they feasible?
    Marasini N; Kaminskas LM
    Drug Dev Ind Pharm; 2019 Jun; 45(6):882-894. PubMed ID: 30767591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subunit vaccines of the future: the need for safe, customized and optimized particulate delivery systems.
    Foged C
    Ther Deliv; 2011 Aug; 2(8):1057-77. PubMed ID: 22826868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent developments in vaccine delivery systems.
    O'Hagan DT
    Curr Drug Targets Infect Disord; 2001 Nov; 1(3):273-86. PubMed ID: 12455401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selection of adjuvants for vaccines targeting specific pathogens.
    Sarkar I; Garg R; van Drunen Littel-van den Hurk S
    Expert Rev Vaccines; 2019 May; 18(5):505-521. PubMed ID: 31009255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Particulate vaccines: on the quest for optimal delivery and immune response.
    De Temmerman ML; Rejman J; Demeester J; Irvine DJ; Gander B; De Smedt SC
    Drug Discov Today; 2011 Jul; 16(13-14):569-82. PubMed ID: 21570475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanoparticulate Carriers Used as Vaccine Adjuvant Delivery Systems.
    Wang N; Qian R; Liu T; Wu T; Wang T
    Crit Rev Ther Drug Carrier Syst; 2019; 36(5):449-484. PubMed ID: 32421952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvants for veterinary vaccines--types and modes of action.
    Gerdts V
    Berl Munch Tierarztl Wochenschr; 2015; 128(11-12):456-63. PubMed ID: 26697712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving vaccine delivery using novel adjuvant systems.
    Pichichero ME
    Hum Vaccin; 2008; 4(4):262-70. PubMed ID: 18398303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Updated Review of ISCOMSTM and ISCOMATRIXTM Vaccines.
    Garcia A; Lema D
    Curr Pharm Des; 2016; 22(41):6294-6299. PubMed ID: 27634183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Adjuvants--essential components of new generation vaccines].
    Dzierzbicka K; Kołodziejczyk AM
    Postepy Biochem; 2006; 52(2):204-11. PubMed ID: 17078510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in vaccine adjuvants.
    Singh M; O'Hagan DT
    Pharm Res; 2002 Jun; 19(6):715-28. PubMed ID: 12134940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IC31 and IC30, novel types of vaccine adjuvant based on peptide delivery systems.
    Lingnau K; Riedl K; von Gabain A
    Expert Rev Vaccines; 2007 Oct; 6(5):741-6. PubMed ID: 17931154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators.
    Nordly P; Madsen HB; Nielsen HM; Foged C
    Expert Opin Drug Deliv; 2009 Jul; 6(7):657-72. PubMed ID: 19538037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The development and use of vaccine adjuvants.
    Edelman R
    Mol Biotechnol; 2002 Jun; 21(2):129-48. PubMed ID: 12059113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems.
    Garçon N; Van Mechelen M
    Expert Rev Vaccines; 2011 Apr; 10(4):471-86. PubMed ID: 21506645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in veterinary vaccine adjuvants.
    Singh M; O'Hagan DT
    Int J Parasitol; 2003 May; 33(5-6):469-78. PubMed ID: 12782048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanotechnology in vaccine delivery.
    Peek LJ; Middaugh CR; Berkland C
    Adv Drug Deliv Rev; 2008 May; 60(8):915-28. PubMed ID: 18325628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucosal delivery of vaccine antigens and its advantages in pediatrics.
    De Magistris MT
    Adv Drug Deliv Rev; 2006 Apr; 58(1):52-67. PubMed ID: 16516335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.